Q3 2016 EPS Estimates for Sarepta Therapeutics Inc. (SRPT) Decreased by Jefferies Group
Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Equities researchers at Jefferies Group decreased their Q3 2016 earnings per share estimates for shares of Sarepta Therapeutics in a research note issued to investors on Monday. Jefferies Group analyst G. Wang now anticipates that the brokerage will post earnings per share of ($1.38) for the quarter, down from their previous estimate of ($1.31). Jefferies Group currently has a “Hold” rating and a $50.00 price target on the stock. Jefferies Group also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($0.51) EPS, FY2016 earnings at ($4.51) EPS, FY2017 earnings at ($2.90) EPS, FY2018 earnings at ($0.15) EPS, FY2019 earnings at $2.49 EPS and FY2020 earnings at $3.89 EPS.
Several other research firms also recently commented on SRPT. Oppenheimer Holdings Inc. lifted their price objective on Sarepta Therapeutics from $60.00 to $76.00 in a report on Monday. JMP Securities upgraded Sarepta Therapeutics to an “outperform” rating and lifted their price objective for the stock from $10.00 to $60.00 in a report on Monday. Wedbush reiterated an “outperform” rating and issued a $66.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday. SunTrust Banks Inc. upgraded Sarepta Therapeutics to a “reduce” rating and lifted their price objective for the stock from $4.00 to $48.00 in a report on Tuesday. Finally, WBB Securities reiterated a “strong-buy” rating and issued a $60.00 price objective (up from $40.00) on shares of Sarepta Therapeutics in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Sarepta Therapeutics has a consensus rating of “Buy” and an average target price of $51.01.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 56.22 on Wednesday. The stock’s market capitalization is $2.69 billion. The stock has a 50 day moving average of $29.05 and a 200-day moving average of $21.62. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $58.87.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period in the previous year, the firm earned ($0.87) EPS.
In other news, VP Jayant Aphale sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the transaction, the vice president now owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Edward M. Md Kaye sold 24,352 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,217,600.00. Following the transaction, the chief executive officer now directly owns 89,983 shares in the company, valued at approximately $4,499,150. The disclosure for this sale can be found here. 10.90% of the stock is owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors increased its position in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares in the last quarter. State Street Corp increased its position in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares in the last quarter. Commonwealth Equity Services Inc bought a new position in Sarepta Therapeutics during the second quarter valued at $302,000. National Planning Corp increased its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock valued at $4,230,000 after buying an additional 11,334 shares in the last quarter. 72.09% of the stock is currently owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.